Company Performance Metrics
- Navid Gholampour: Chief Executive Officer
Hlx Life Sciences develops peptide-based biologic therapies focused on oncology and immune-related disorders. The company engineers multifunctional peptides that aim to modulate key signaling pathways involved in tumor growth, immune evasion, and chronic inflammation. The pipeline combines therapeutic peptides with antibody and protein platforms to
improve selectivity, stability, and targeted delivery. Research programs explore applications in solid tumors and hematologic malignancies, along with conditions driven by dysregulated immune responses. Hlx Life Sciences emphasizes translational research, moving candidates from discovery through preclinical validation toward clinical development in collaboration with partners across the biopharma ecosystem.
